NCT06246916A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3

NCT05929664Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Phase 2

NCT07433673Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Phase 2

+2 more

Dupilumab

Prurigo Nodularis

N/A

Sodium-glucose cotransporter 2 inhibitors

Diabetic Nephropathies

N/A

Non-Interventional

Hemophilia B

N/A

Clinical Trials (3)

NCT05673967Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

N/A

NCT05568459A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

N/A

NCT05338892Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

N/A

Odronextamab

Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

N/A

Clinical Trials (5)

NCT06091865A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase 3

NCT06149286A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 3

NCT05685173A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Phase 1

+2 more

Aspirin

Healthy Volunteer

N/A

Clinical Trials (1)

NCT05546957Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

N/A

Dupilumab

Type 2 Inflammatory Disorders

N/A

Clinical Trials (1)

NCT04776694Compassionate Use of Dupilumab

N/A

aflibercept 2 mg

Retinal Vasculitis

N/A

Clinical Trials (1)

NCT06769412A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

N/A

Intravitreal Aflibercept Injection

Age-Related Macular Degeneration

N/A

Clinical Trials (1)

NCT01773954Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

N/A

Aflibercept

Retinal Vein Occlusion

N/A

Parkinson's Disease Progression Study

Parkinson Disease

N/A

Aflibercept

Retinal Vein Occlusion

N/A

Aflibercept

Wet Macular Degeneration

N/A

Dupilumab

Atopic Dermatitis

N/A

Dupilumab

Atopic Dermatitis

N/A

Visit 1: Clinical exam and questionnaires

Asthma

N/A

University of Michigan "Nephrology Research BioBank"

Chronic Kidney Disease

N/A

Clinical Trials (1)

NCT00381121University of Michigan "Nephrology Research BioBank"

N/A

REGN2810

Advanced Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT06269133Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

N/A

Aflibercept

Wet Macular Degeneration

N/A

Surveys

Post-acute COVID-19 (PACS), or "long COVID" Syndrome

N/A

Clinical Trials (3)

NCT05013723Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

N/A

NCT07217535Rutgers University Study of the Genetics of Kidney Disease

N/A

NCT06773897Rutgers University Study of the Genetics of Breast Cancer.

N/A

dupilumab

Eosinophilic Esophagitis (EoE)

N/A

Cemiplimab

Cutaneous Squamous Cell Carcinoma (CSCC)

N/A

Clinical Trials (1)

NCT07064330Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

N/A

Non-interventional

Long Term Safety Following GM T Cell Therapy

N/A

Clinical Trials (1)

NCT06798298A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

N/A

Fianlimab + Cemiplimab

Locally Advanced Melanoma

N/A

Clinical Trials (1)

NCT07223411Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

N/A

cemiplimab

Cutaneous Squamous Cell Carcinoma

N/A

Non Applicable

Intraocular Inflammation

N/A

There is no intervention

Diabetic Nephropathies

N/A

Aflibercept

Diabetic Retinopathy